Budapest, Hungary

Ildiko Kiraly


Average Co-Inventor Count = 6.0

ph-index = 3

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 1978-1981

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Ildiko Kiraly: Innovator in Ergoline Compounds

Introduction

Ildiko Kiraly is a notable inventor based in Budapest, Hungary. She has made significant contributions to the field of medicinal chemistry, particularly in the development of ergoline derivatives. With a total of three patents to her name, her work has implications for pharmacology and therapeutic applications.

Latest Patents

Ildiko Kiraly's latest patents include innovative compounds that exhibit unique properties. One of her notable inventions is related to novel ergol-8-ene and ergoline derivatives, which are characterized by a specific general formula. This invention focuses on new compounds that possess antiserotonin and hypotensive effects, acting upon the central nervous system. Another patent involves compounds of ergolene and ergoline structure, which also includes pharmaceutically acceptable acid addition salts. These compounds are designed to enhance therapeutic efficacy and provide new avenues for treatment.

Career Highlights

Ildiko Kiraly is associated with Richter Gedeon Vegyeszeti Gyar Rt, a prominent pharmaceutical company in Hungary. Her work at this institution has allowed her to explore and develop innovative solutions in the field of medicinal chemistry. Her research has contributed to advancements in drug development and therapeutic applications.

Collaborations

Ildiko has collaborated with several professionals in her field, including Erzsebet Mago Nee Karacsony and Jozsef Borsi. These collaborations have fostered a productive environment for innovation and research, leading to significant advancements in their shared areas of expertise.

Conclusion

Ildiko Kiraly's contributions to the field of ergoline compounds highlight her role as a key innovator in medicinal chemistry. Her patents reflect her commitment to advancing pharmaceutical science and improving therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…